Gilead Sciences, Inc. with ticker code (GILD) now have 25 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $111.64 and $63.66 calculating the mean target share price we have $78.46. (at the time of writing). Now with the previous closing price of $69.55 this indicates there is a potential upside of 12.8%. There is a 50 day moving average of $74.22 and the 200 day MA is $77.09. The company has a market capitalization of 86.08B. The stock price for the company is currently $69.04 USD
The potential market cap would be $97,112,807,659 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 15.34, revenue per share of $21.73 and a 9.78% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
